A Phase III, Multicenter, Randomized Study to Assess the Efficacy and Safety of 0,5 mg Tizaspray Administered Intranasally Versus Sirdalud 2 mg Tablets, in Patients With Acute Low Back Pain
Latest Information Update: 10 Mar 2022
At a glance
- Drugs Tizanidine (Primary) ; Tizanidine
- Indications Back pain
- Focus Registrational; Therapeutic Use
- Sponsors MDM SpA
Most Recent Events
- 15 May 2017 Status changed from recruiting to completed.
- 12 Mar 2015 New trial record